„Inclisiran“ – Versionsunterschied
[ungesichtete Version] | [ungesichtete Version] |
Keine Bearbeitungszusammenfassung | →top: Specify | ||
Zeile 49: | Zeile 49: | ||
}} | }} | ||
'''Inclisiran''' (development codes '''ALN-PCSsc''', '''ALN-60212''') is an experimental drug for the treatment of elevated cholesterol. It is a [[small interfering RNA]] that inhibits [[translation (biology)|translation]] of the protein [[PCSK9]].<ref>{{cite journal | vauthors = Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A | display-authors = 6 | title = A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 | journal = The New England Journal of Medicine | volume = 376 | issue = 1 | pages = 41–51 | date = January 2017 | pmid = 27959715 | pmc = 5778873 | doi = 10.1056/NEJMoa1609243 }}</ref><ref name="Spreitzer">{{cite journal | vauthors = Spreitzer H | title = Neue Wirkstoffe: Inclisiran | journal = Österreichische Apotheker-Zeitung | date = 11 September 2017 | issue = 19/2017 | language = German}}</ref><ref>{{cite journal |title=Proposed INN: List 114 |journal=WHO Drug Information |volume=29 |issue=4 |year=2015 |pages=531f |publisher=[[World Health Organization|WHO]] |url= http://www.who.int/medicines/publications/druginformation/issues/PL_114.pdf?ua=1 }}</ref> | '''Inclisiran''' (development codes '''ALN-PCSsc''', '''ALN-60212''') is an experimental drug for the treatment of [[Hypercholesterolemia|elevated cholesterol]], more specifically [[familial hypercholesterolaemia]]. It is a [[small interfering RNA]] that inhibits [[translation (biology)|translation]] of the protein [[PCSK9]].<ref>{{cite journal | vauthors = Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A | display-authors = 6 | title = A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 | journal = The New England Journal of Medicine | volume = 376 | issue = 1 | pages = 41–51 | date = January 2017 | pmid = 27959715 | pmc = 5778873 | doi = 10.1056/NEJMoa1609243 }}</ref><ref name="Spreitzer">{{cite journal | vauthors = Spreitzer H | title = Neue Wirkstoffe: Inclisiran | journal = Österreichische Apotheker-Zeitung | date = 11 September 2017 | issue = 19/2017 | language = German}}</ref><ref>{{cite journal |title=Proposed INN: List 114 |journal=WHO Drug Information |volume=29 |issue=4 |year=2015 |pages=531f |publisher=[[World Health Organization|WHO]] |url= http://www.who.int/medicines/publications/druginformation/issues/PL_114.pdf?ua=1 }}</ref> | ||
It is being developed by [[The Medicines Company]] which licensed the rights to inclisiran from [[Alnylam Pharmaceuticals]].<ref>{{cite web | first = Nick Paul | last = Taylor | name-list-format = vanc |title=Medicines Company's PCSK9 drug hits phase 3 efficacy goals |url=https://www.fiercebiotech.com/biotech/medicines-company-s-pcsk9-drug-hits-phase-3-efficacy-goals | work = FierceBiotech | date = 26 August 2019 }}</ref> | It is being developed by [[The Medicines Company]] which licensed the rights to inclisiran from [[Alnylam Pharmaceuticals]].<ref>{{cite web | first = Nick Paul | last = Taylor | name-list-format = vanc |title=Medicines Company's PCSK9 drug hits phase 3 efficacy goals |url=https://www.fiercebiotech.com/biotech/medicines-company-s-pcsk9-drug-hits-phase-3-efficacy-goals | work = FierceBiotech | date = 26 August 2019 }}</ref> | ||
Version vom 4. Juni 2020, 08:06 Uhr
Inclisiran (development codes ALN-PCSsc, ALN-60212) is an experimental drug for the treatment of elevated cholesterol, more specifically familial hypercholesterolaemia. It is a small interfering RNA that inhibits translation of the protein PCSK9.[1][2][3] It is being developed by The Medicines Company which licensed the rights to inclisiran from Alnylam Pharmaceuticals.[4]
In 2019 The Medicines Company announced positive results from pivotal phase III study (all primary and secondary endpoints were met with efficacy consistent with Phase I and II studies). The company anticipates regulatory submissions in the U.S. in the fourth quarter of 2019, and in Europe in the first quarter of 2020.[5] The Medicines Company is being acquired by Novartis.[6]
References
Further reading
- Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ: Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. In: N. Engl. J. Med. 376. Jahrgang, Nr. 15, April 2017, S. 1430–1440, doi:10.1056/NEJMoa1615758, PMID 28306389 (uu.nl [PDF]).
- Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PL, Kastelein JJ: Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. In: N. Engl. J. Med. März 2020, doi:10.1056/NEJMoa1912387, PMID 32187462.
External links
- Inclisiran. In: Drug Information Portal. U.S. National Library of Medicine
- Vorlage:ClinicalTrialsGov
- Vorlage:ClinicalTrialsGov
Vorlage:Cardiovascular-drug-stub
- ↑ Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A: A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. In: The New England Journal of Medicine. 376. Jahrgang, Nr. 1, Januar 2017, S. 41–51, doi:10.1056/NEJMoa1609243, PMID 27959715, PMC 5778873 (freier Volltext).
- ↑ Spreitzer H: Neue Wirkstoffe: Inclisiran. In: Österreichische Apotheker-Zeitung. Nr. 19/2017, 11. September 2017.
- ↑ Proposed INN: List 114. In: WHO Drug Information. 29. Jahrgang, Nr. 4. WHO, 2015, S. 531 f. (who.int [PDF]).
- ↑ Nick Paul Taylor: Medicines Company's PCSK9 drug hits phase 3 efficacy goals. In: FierceBiotech. 26. August 2019 .
- ↑ The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran. In: The Medicines Company. Abgerufen am 29. August 2019.
- ↑ Novartis acquires medicines company. In: Novartis. Abgerufen am 15. Januar 2020.